BRYNOVIN (sitagliptin hydrochloride)
Brynovin helps adults with type 2 diabetes manage their blood sugar levels when used alongside diet and exercise. It is prescribed to improve glycemic control by supporting the body's natural processes for regulating glucose. This medication is not intended for patients with type 1 diabetes or for those who have a history of pancreatitis.
How BRYNOVIN Works
This drug works by blocking the DPP-4 enzyme, which prevents the breakdown of incretin hormones that are naturally released after a meal. By keeping these hormones active for longer, the medication prompts the pancreas to release more insulin and signals the liver to produce less sugar. This process helps regulate blood sugar in a glucose-dependent manner, responding to the body's needs throughout the day.
Details
- Status
- Prescription
- First Approved
- 2025-01-16
- Patent Cliff
- 2040
- Routes
- ORAL
- Dosage Forms
- SOLUTION
BRYNOVIN Approval History
What BRYNOVIN Treats
1 indicationsBRYNOVIN is approved for 1 conditions since its original approval in 2025. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Type 2 Diabetes
BRYNOVIN Target & Pathway
ProTarget
A hormone released after eating that stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety. GLP-1 receptor agonists mimic these effects, improving blood sugar control and promoting weight loss in diabetes and obesity.
BRYNOVIN Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in BRYNOVIN's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications BRYNOVIN treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to BRYNOVIN
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
BRYNOVIN FDA Label Details
Indications & Usage
FDA Label (PDF)BRYNOVIN is indicated for the treatment of Type 2 Diabetes.
BRYNOVIN Patents & Exclusivity
Patents (2 active)
Pro Intelligence Preview
Deep insights for BRYNOVIN
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2040
- • 2 active patents
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • 20 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.